Literature DB >> 19754429

miRNPs: versatile regulators of gene expression in vertebrate cells.

Joan A Steitz1, Shobha Vasudevan.   

Abstract

TNFalpha (tumour necrosis factor alpha) mRNA bears in its 3'-UTR (untranslated region) a conserved ARE (AU-rich element), a signal that exerts tight post-transcriptional control over the expression of TNFalpha and other cytokines. We found that the TNFalpha ARE increases translational efficiency when cell growth is arrested, a physiologically relevant state occurring during inflammation, angiogenesis and monocyte differentiation. Under these conditions, called quiescence, the miRNP (microribonucleoprotein)-associated proteins FXR1 (Fragile X mental retardation-related protein 1) and AGO2 (Argonaute 2), which are usually considered negative regulators, are transformed into effector molecules that bind the ARE to activate translation. We then identified a specific miRNA (microRNA) that directs the association of AGO2 and FXR1 with the ARE during translational up-regulation. Two other well-characterized miRNAs likewise promote translation activation in quiescent or in contact-inhibited cells; yet, they repress translation in proliferating cells in the late S/G(2)-phase. We conclude that translational regulation by miRNPs oscillates between repression and activation as a function of the cell cycle. The activating role of miRNAs is now being confirmed in the immature Xenopus oocyte, which mimics the quiescent state.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19754429     DOI: 10.1042/BST0370931

Source DB:  PubMed          Journal:  Biochem Soc Trans        ISSN: 0300-5127            Impact factor:   5.407


  31 in total

1.  A KLF4-miRNA-206 autoregulatory feedback loop can promote or inhibit protein translation depending upon cell context.

Authors:  Chen-Chung Lin; Ling-Zhi Liu; Joseph B Addison; William F Wonderlin; Alexey V Ivanov; J Michael Ruppert
Journal:  Mol Cell Biol       Date:  2011-04-25       Impact factor: 4.272

Review 2.  Control of cytokine mRNA expression by RNA-binding proteins and microRNAs.

Authors:  V Palanisamy; A Jakymiw; E A Van Tubergen; N J D'Silva; K L Kirkwood
Journal:  J Dent Res       Date:  2012-02-01       Impact factor: 6.116

3.  Individual microRNAs (miRNAs) display distinct mRNA targeting "rules".

Authors:  Wang-Xia Wang; Bernard R Wilfred; Kevin Xie; Mary H Jennings; Yanling Hu Hu; Arnold J Stromberg; Peter T Nelson
Journal:  RNA Biol       Date:  2010 May-Jun       Impact factor: 4.652

Review 4.  MicroRNA-Based Therapeutic Strategies for Targeting Mutant and Wild Type RAS in Cancer.

Authors:  Sriganesh B Sharma; John Michael Ruppert
Journal:  Drug Dev Res       Date:  2015-08-18       Impact factor: 4.360

Review 5.  Posttranscriptional regulation of FOXO expression: microRNAs and beyond.

Authors:  P Urbánek; L-O Klotz
Journal:  Br J Pharmacol       Date:  2016-05-02       Impact factor: 8.739

6.  MicroRNA-19 (miR-19) regulates tissue factor expression in breast cancer cells.

Authors:  Xiaoxi Zhang; Haijun Yu; Jessica R Lou; Jie Zheng; Hua Zhu; Narcis-Ioan Popescu; Florea Lupu; Stuart E Lind; Wei-Qun Ding
Journal:  J Biol Chem       Date:  2010-11-08       Impact factor: 5.157

7.  Myc target gene, long intergenic noncoding RNA, Linc00176 in hepatocellular carcinoma regulates cell cycle and cell survival by titrating tumor suppressor microRNAs.

Authors:  D D H Tran; C Kessler; S E Niehus; M Mahnkopf; A Koch; T Tamura
Journal:  Oncogene       Date:  2017-09-04       Impact factor: 9.867

8.  Translational control of cyclins.

Authors:  Woan-Yuh Tarn; Ming-Chih Lai
Journal:  Cell Div       Date:  2011-02-11       Impact factor: 5.130

Review 9.  Computational methods to identify miRNA targets.

Authors:  Molly Hammell
Journal:  Semin Cell Dev Biol       Date:  2010-01-15       Impact factor: 7.727

Review 10.  Post-transcriptional control during chronic inflammation and cancer: a focus on AU-rich elements.

Authors:  Khalid S A Khabar
Journal:  Cell Mol Life Sci       Date:  2010-05-22       Impact factor: 9.261

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.